| Jeanna Harvey Barnes, | |
|
55 Fruit Street, Founders Building, Suite 202, Boston, MA 02114 | |
| (561) 901-1023 | |
| Not Available |
| Full Name | Jeanna Harvey Barnes |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 9 Years |
| Location | 55 Fruit Street, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083008999 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhode Island Hospital | Providence, RI | Hospital |
| Kent County Memorial Hospital | Warwick, RI | Hospital |
| The Miriam Hospital | Providence, RI | Hospital |
| Sturdy Memorial Hospital | Attleboro, MA | Hospital |
| Newport Hospital | Newport, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rhode Island Medical Imaging | 8022097815 | 108 |
| Rhode Island Medical Imaging | 8022097815 | 108 |
News Archive
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that it has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa (RP). RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today.
EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announced multiple activities to showcase its Advanced Orthopedic Solutions at the American Association of Hip and Knee Surgeons Annual Meeting, being held November 7-10, 2019 in Dallas, Texas.
Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.
The vast majority of homeless adults surveyed in a national study had trouble accessing at least one type of needed health care service in the preceding year, according to a study that will appear in the July American Journal of Public Health and is now available online.
› Verified 5 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that it has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa (RP). RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today.
EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announced multiple activities to showcase its Advanced Orthopedic Solutions at the American Association of Hip and Knee Surgeons Annual Meeting, being held November 7-10, 2019 in Dallas, Texas.
Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.
The vast majority of homeless adults surveyed in a national study had trouble accessing at least one type of needed health care service in the preceding year, according to a study that will appear in the July American Journal of Public Health and is now available online.
› Verified 5 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that it has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa (RP). RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today.
EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announced multiple activities to showcase its Advanced Orthopedic Solutions at the American Association of Hip and Knee Surgeons Annual Meeting, being held November 7-10, 2019 in Dallas, Texas.
Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.
The vast majority of homeless adults surveyed in a national study had trouble accessing at least one type of needed health care service in the preceding year, according to a study that will appear in the July American Journal of Public Health and is now available online.
› Verified 5 days ago
| Entity Name | Rhode Island Medical Imaging |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942376033 PECOS PAC ID: 8022097815 Enrollment ID: O20180523000302 |
News Archive
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that it has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa (RP). RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today.
EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announced multiple activities to showcase its Advanced Orthopedic Solutions at the American Association of Hip and Knee Surgeons Annual Meeting, being held November 7-10, 2019 in Dallas, Texas.
Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.
The vast majority of homeless adults surveyed in a national study had trouble accessing at least one type of needed health care service in the preceding year, according to a study that will appear in the July American Journal of Public Health and is now available online.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeanna Harvey Barnes, 55 Fruit Street, Founders Bldg 202, Boston, MA 02114 Ph: () - | Jeanna Harvey Barnes, 55 Fruit Street, Founders Building, Suite 202, Boston, MA 02114 Ph: (561) 901-1023 |
News Archive
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced that it has received orphan drug designation in the European Union for unoprostone isopropyl for the treatment of retinitis pigmentosa (RP). RP is a genetic disease characterized by progressive, irreversible vision loss and decreasing visual acuity, and there are no drugs or therapeutic procedures currently approved for the treatment of RP today.
EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announced multiple activities to showcase its Advanced Orthopedic Solutions at the American Association of Hip and Knee Surgeons Annual Meeting, being held November 7-10, 2019 in Dallas, Texas.
Mylan Inc. today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist compound for various indications.
The vast majority of homeless adults surveyed in a national study had trouble accessing at least one type of needed health care service in the preceding year, according to a study that will appear in the July American Journal of Public Health and is now available online.
› Verified 5 days ago
Jennifer Michelle Thomas, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Department Of Radiology, Boston, MA 02115 Phone: 617-732-6248 | |
Dr. Meghavi Mashar, MB BCHIR Radiology Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-667-7000 | |
Rafeeque A Bhadelia, M.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Bidmc Wcc90, Boston, MA 02215 Phone: 617-754-2058 Fax: 617-754-2004 | |
Dr. Srinivasan Mukundan Jr., M.D. Radiology Medicare: Medicare Enrolled Practice Location: 75 Francis St, Brigham And Women's Hospital, Boston, MA 02115 Phone: 617-732-7260 | |
Raymond W Liu, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St, Grb 293, Boston, MA 02114 Phone: 917-923-2079 | |
Dr. Hillary R. Kelly, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Grb-273a, Boston, MA 02114 Phone: 617-726-8320 Fax: 617-724-3338 | |
Dr. Tina Young Poussaint, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6450 |